STX expects U.S. ACCRUFER control to double EBIT and lift margins
Shield Therapeutics expects full U.S. commercial control of ACCRUFER® to double EBIT and expand gross profit margins to 75%-80%, with no upfront payment and immediate accretion, supporting 2026 growth and profitability targets.
Full U.S. commercial control of ACCRUFER® is expected to double EBIT and expand gross profit margins to 75%-80%, with no upfront payment and immediate accretion.
The expanded sales force and platform support future growth and profitability targets for 2026.Based on Shield Therapeutics Plc [STX] Sta…